Background: Folliculitis Decalvans is a neutrophilic infammation of the scalp characterized by painful recurrent purulent follicular exsudation resulting in primary cicatricial alopecia. Etiology is unclear but infection may play a role. Systemic antimicrobial agents, namely tetracyclines, are useful to control the disease.
Introduction
Folliculitis Decalvans (FD) is a rare neutrophilic inflammation of the scalp characterized by painful recurrent purulent follicular exudation resulting in primary cicatricial alopecia. Although it is not an infection, bacterial superantigens may trigger inflammation [1] and antimicrobials, namely tetracyclines, have been tried previously with good results [2] [3] [4] [5] [6] [7] [8] and are often the first therapeutic approach.
There are also anedoctal improvements reported with isotretinoin, dapsone, adalimumab and infliximab, topical tacrolimus, ndYag-LASER and photodynamic therapy [6, [9] [10] [11] [12] [13] [14] [15] [16] . Most of our FD patients are treated with minocycline. However, in south European countries tetracycline is avoided from May to October due to its hyperpigmentation potential. Thus, an antimicrobial drug effective in FD but without photosensibilization potential would be optimal. The beneficial effect of azithromycin in acne is well known [17] [18] [19] [20] [21] , used both in monotherapy [17] [18] [19] and in combination with isotretinoin [20, 21] . The authors present a case series of 19 patients with FD treated successfully with azithromycin in monotherapy.
Material and Methods
Inclusion: Patients presenting to our hair clinic from 01/01/10 to 31/12/12 with first diagnosis of active Folliculitis Decalvans (FD). Active FD was defined clinically: inflammatory perifollicular papules, papulo-crusts and pustules in Figure 1 and by dermoscopy: follicular tufts, perifollicular erythema, crusts and pustules.
Patients with residual FD lesions of residual cicatricial alopecia ( Figure 2 ) were excluded.
A detailed clinical history followed by a thorough scalp examination and routine systemic examination were performed. The severity of the disease was assessed based on objective and subjective criteria. Objective criteria: the total number of papules, papulo-crusts and pustules on the scalp. Subjective criteria: global score 0-6 based in addition of partial score regarded to putties (0-2), burn sensation (0-2) and pain (0-2).
Patients with previous medication waited six months after stopping it before being enrolled. The patients were prescribed with azihtromycin 500mg/day for 3 consecutive days every 2 weeks.
The severity of the disease was assessed before treatment and after 1, 3 and 6 months. Primary end point was the change in the number of lesions and secondary end point the change in subjective global score.
T-student test was used for statistical analysis.
Results
There were 15 males and 4 females, with 18 to 59 years of age, with a mean age of 27 years old. The course of the disease varied from 5 weeks to 17 months. Common complaints were pain (10 patients), burn sensation (8 patients), pruritus (3 patients) and hair loss (6 patients). Familial history of the disease was found in 3 patients. Vertex involvement was seen in 12 patients and occipital involvement in 9. Three patiens had papules or pustulae all over the scalp. Papular or pustular lesions were observed in all patients and areas of cicatricial alopecia in 11 patients. Tufted hairs (clinicaly or dermoscopy) were present in 18 patients. Table 1 refer to clinical data of the patients and Table 2 to the number of papular, papulo-crust and pustular lesions ( Figure 3 ) over time, respectively. The change in this number over time is showed in Figure 4 and the change in subjective global score (0-6) obtained by adition of partial scores of pruritus (0-2), pain (0-2) and burn sensation (0-2) in Figure 5 .
Discussion
Our group of patients has a male predominance observed in other studies as well. In patients with FD minocycline is our first choice, usually in monotherapy. In some non-responsive patients we associated rifampicin or clarithromycin. The main reason for the study is that minocycline use is associated with hiperpigmentation [22, 23] and this adverse effect may limit its use during summertime. Due to this fact, often, we stop the drug from may to october, with concomitant worsening of FD in the majority of patients.
The primary end point of our study with azythromycin was the change in total number of papules, papulo-crusts and pustules and it has been chosen for being a very exact and measurable criteria. The level of inflammation and the progression to areas of cicatricial alopecia are more important clinical criteria but more difficult to measure with accuracy. In our FD patients azithromycin was clearly able to reduce the total number of lesions. The differences between initial number and lesions and post-treatment number of lesions are highly significant and cannot be justified by fluctuation in disease activity (if we consider that in a population of FD patients this number will not decease over time, we have a t student p< 0.0001).
The clear reduction in subjective global score (secondary endpoint) reveals that azitromycine is able to improve symptoms (pruritus, pain, burn sensation).
Probably, this action may be due both to antiinflammatory [24] [25] [26] and antimicrobial [27] properties of azithromycin (a recent sudy showed lower resistence of Propionibacterium acnes to this drug than to clindamycin, erythromycin, oxytetracycline, or doxycycline).
Several oral antibiotics wheter used in monotherapy or in association showed some effectiveness in FD patients. Relapses are frequently observed after discontinuation of the antibiotic and patients might have to stay on low dose antibiotics for quite some time. Ryfampicin at a dose of 300 mg bid 10-12 weeks is known to be a good antistaphylococcal agent and eliminating long-term carriers. Nowadays it is recommended to use rifampicin in combination with clindamycin to avoid emergence of resistance and in order to achieve high intracellular concentration which results in a potential to eradicate S. aureus [28] However, this therapeutical association might cause a higher incidence of adverse effects, a reason why azithromycin should be considered to be a valid treatment choice.
No patient complaint of adverse effects with this treatment.
In our opinion, this benefic action in FD course may turn this drug a good candidate for minocycline substitution during summertime in countries in which sun expose may induce minocycline hyperpigmentation.
